Economic analysis of rapid multiplex polymerase chain reaction testing for meningitis/encephalitis in pediatric patients
© 2018 Future Medicine Ltd. Aim: We assessed the possible economic impact of a rapid test in pediatric patients with suspected community-acquired meningitis/encephalitis. Materials & methods: Modeling simulated diagnosis, clinical decisions, resource use/costs of standard of care (SOC) and two cerebrospinal fluid testing strategies using FilmArray®(FA), a US FDA-cleared system that provides results in approximately 1 h. Results: Pathogens detected by FA caused approximately 75% of cases, 97% of which would be accurately diagnosed with FA. Mean cost/case ranged from 17,599 to 22,025. Syndromic testing is less expensive than SOC. Testing all suspected cases yielded greater savings (3481/case) than testing only those with abnormal cerebrospinal fluid (2157/case). Conclusion: Greater economic benefits are achievable with syndromic testing of all cases, rather than SOC or targeted syndromic testing.
617 - 629
School of Medicine
Pathology and Laboratory Medicine
This document is currently not available here.
Hofstra Northwell School of Medicine and Northwell Health currently do not subscribe to this title. If you are an affiliate and would like to access the full text please request it via interlibrary loan via Hofstra Northwell School of Medicine ILL (faculty and students only) or Northwell Health ILL